Plonmarlimab

Phase 3Monoclonal antibody

TTJ Biopharma Co., Ltd.

Plonmarlimab is one of 91 small molecule programs targeting Relapsed/Refractory. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed/refractoryRecruiting

ArthritisNot yet recruiting

Relapsed/refractoryPhase 3

Recruiting

ArthritisPhase 2

Not yet recruiting

Competition

Competitive Landscape

64 competitors in Relapsed/refractory

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

9 2

Rituxan

Roche

Phase 2

9 3

Venclexta

AbbVie

Phase 2

8 4

Fludara

Sanofi

Phase 2

7 5

Opdivo

Bristol-Myers Squibb

Phase 2

4 6

Keytruda

Merck & Co.

Phase 2

4 7

Gemzar

Johnson & Johnson

Phase 2

2 8

Adcetris

Pfizer

Phase 2

2 9

Mektovi

Pfizer

Phase 2

1 10

Thalomid

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Relapsed/refractory

NCT07208058

Phase 2Not yet recruiting

Arthritis

NCT07453004

Clinical

Trials by Indication[1]

Macrophage Activation Syndrome1 trial

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))

Completed·TTJ Biopharma Co., Ltd.·Phase 2·NCT07034209·18 enrolled

Arthritis1 trial

A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis

Not yet recruiting·TTJ Biopharma Co., Ltd.·Phase 2·NCT07453004·170 enrolled

Relapsed/Refractory1 trial

An Open-label, Single-arm, Multicenter, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])

Recruiting·TTJ Biopharma Co., Ltd.·Phase 3·NCT07208058·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Plonmarlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plonmarlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plonmarlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TJ Biopharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: TTJ Biopharma Co., Ltd.

Plonmarlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Macrophage Activation Syndrome1 trial

Arthritis1 trial

Relapsed/Refractory1 trial

References

Drug Info

Quick Facts

Related News